Capsaicin

證據等級: L5

預測適應症: 10 個

Capsaicin: From Neuropathic Pain to Otitis Externa

One-Sentence Summary

Capsaicin is a TRPV1 receptor agonist derived from hot peppers, recognized globally as a topical analgesic for neuropathic and musculoskeletal pain, with no registered indications in the current regulatory dataset. The TxGNN model’s top prediction identifies Otitis Externa as a potential new indication; however, the sole supporting literature (PMID 12769482) uses capsaicin as an inflammation-inducing tool in animal models — the mechanistic direction is opposite to therapeutic intent. With 0 clinical trials and 1 preclinical publication (tool compound role, not therapeutic use), the evidence level is L5 and the recommendation is Hold.

Quick Overview

Item	Content
Original Indication	Not registered in current dataset (global use: neuropathic pain, musculoskeletal pain)
Predicted New Indication	Otitis Externa
TxGNN Prediction Score	98.76%
Evidence Level	L5
EU Market Status	✗ Not marketed (0 authorizations in dataset)
Number of Authorizations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Formal mechanism of action data is not available in this dataset. Based on established pharmacological knowledge, capsaicin is the active pungent compound in chili peppers and a highly selective agonist at the TRPV1 (Transient Receptor Potential Vanilloid 1) channel — a calcium-permeable ion channel expressed on peripheral nociceptors. Its paradoxical analgesic effect proceeds in two phases: acute TRPV1 activation triggers an initial burning sensation, followed by sustained calcium influx that depletes neuropeptides (substance P, CGRP) from C-fiber endings and renders them transiently unresponsive. This “desensitization” mechanism underpins approved pharmaceutical products such as the Qutenza 8% patch, used for postherpetic neuralgia and diabetic peripheral neuropathy in multiple jurisdictions.

TRPV1 receptors are expressed beyond skin tissue, including in the epithelium of the external auditory canal and in mastoid cells. TxGNN’s high prediction score (98.76%) likely reflects this tissue co-expression pattern within the underlying knowledge graph, creating a topologically plausible neurophysiological link between capsaicin’s receptor targets and otitis externa pathology.

The critical problem is mechanistic directionality. Otitis externa is an inflammatory condition of the ear canal, and the only literature in this dataset (PMID 12769482) explicitly employs capsaicin to provoke acute ear inflammation in rodents as a positive-control model — it is a reagent for causing the disease, not treating it. Capsaicin’s initial TRPV1 activation phase amplifies neurogenic inflammation before desensitization sets in; applying it to an already-inflamed and potentially infected ear canal would very likely intensify pain and worsen local inflammation acutely. There is no evidence that subsequent desensitization would produce a net therapeutic benefit in this context. The prediction score reflects co-expression correlations rather than a validated therapeutic opportunity.

Clinical Trial Evidence

Currently no related clinical trials registered for Capsaicin in Otitis Externa.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
12769482	2003	Animal Model / Preclinical	Methods in Molecular Biology	Capsaicin used to induce acute ear inflammation in rodent models (positive control for neurogenic inflammation assays). This is a tool compound application — the mechanistic direction is opposite to a therapeutic role.

EU Market Information

No marketing authorizations for Capsaicin are recorded in the current regulatory dataset (total authorizations: 0; market status: not marketed).

Note: Capsaicin-based pharmaceutical products are known to hold marketing authorizations in multiple international jurisdictions (e.g., Qutenza 179 mg cutaneous patch for peripheral neuropathic pain). The absence of records here may reflect dataset scope limitations and should be verified against the full EMA product database before drawing regulatory conclusions.

Safety Considerations

Formal safety data (warnings, contraindications, drug interactions) is not available in this dataset. Please refer to the SmPC for complete safety information.

In addition, the following topical safety concern is relevant to the predicted indication: capsaicin causes intense burning and local neurogenic inflammation upon first application to sensitized tissue. Direct application to an already-inflamed, potentially infected external ear canal would be expected to cause severe acute pain and could worsen existing inflammation — representing a significant safety barrier independent of the mechanistic direction concern noted above.

Conclusion and Next Steps

Decision: Hold

Rationale: The highest-ranked TxGNN prediction for otitis externa is mechanistically reversed — the only available literature uses capsaicin specifically to cause ear canal inflammation as an experimental model tool, and there are no clinical trials or positive preclinical studies to suggest a therapeutic benefit.

To proceed, the following is needed:

Positive therapeutic preclinical data demonstrating capsaicin treating (rather than inducing) otitis externa, specifically assessing the desensitization phase in an infected/inflamed ear canal environment
Tolerability and safety data for topical capsaicin in the external ear canal
Formal MOA documentation from DrugBank API (Data Gap DG002)
Product monograph download and parsing to complete safety review (Data Gap DG001)

Alternative predictions with stronger evidence (from this same dataset):

Rank	Indication	Evidence Level	Trial	Rationale
2	Post-bacterial disorder	L4	NCT06807164 (Phase 2, n=123, Recruiting)	Three-arm RCT directly comparing capsaicin vs. Serratus Plane Block vs. Botox-A for chronic post-mastectomy neuropathic pain; TRPV1 desensitization mechanism is directly applicable
5	Post-infectious syndrome	L4	3 observational trials + 4 mechanism papers	TRPV1 sensitization in post-infectious IBS documented in clinical cohort (PMID 29051514); TRPV1-resolvin interaction supports desensitization strategy (PMID 33023902)

These two indications represent meaningfully stronger repurposing candidates and would benefit from dedicated evidence packs and deeper review.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.